logo-loader
view4Imprint Group

Promotional products maker 4imprint ‘reaping the rewards of new TV and radio ads’

In March, 4imprint launched a series of TV and radio ads which has resulted in a surge in orders, leaving it on track to top market expectations this year

pens
4imprint can print companies’ logos on virtually anything

Promotional products maker 4imprint Group PLC (LON:FOUR) is “reaping the rewards” of its television and radio adverts, says City broker Peel Hunt.

The £500mln company, which puts companies’ logos on everything from pens to bags to mugs, said today that full-year sales and profits would be towards the “upper end” of current market forecasts.

4imprint upped its marketing spend at the beginning of the year to help build brand awareness and said over summer that early results had “exceeded expectations”.

The marketing drive has “clearly proved a success” said Peel Hunt, with the momentum built up in the first half of the year continuing into the second.

The surge in first-half orders as a result of the ads did pose some problems though, putting pressures on the supply chain which dented margins, although analysts reckon those issues are now behind it.

“Despite strong revenue growth in H1 and today’s confirmation of trading momentum, the stock is currently trading at the lower end of its five-year valuation range,” Peel Hunt added.

As a result, the brokerage has upgraded the stock to ‘buy’ from ‘add’ and hiked its price target to 2,400p (from 2,050p).

Shares jumped 16.6% to 2,110p in mid-morning trade on Thursday.

Quick facts: 4Imprint Group

Price: - -

AQSE:FOUR
Market: AQSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn continues to works on licensing deals as FDA continues its review on...

CytoDyn (OTCQB: CYDY) President and Chief Executive Officer Nader Pourhassan joined Steve Darling from Proactive to discuss a number of issues including the very latest on their clinical trials for a COVID-19 treatment. Pourhassan also told Proactive that they are in discussions with numerous...

11 minutes ago

2 min read